We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Orexigen Therapeutics announces commercialization and distributorship arrangement with Navamedic ASA for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Denmark, Finland, Norway, Sweden and Iceland.